Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-15 of 15 for your search:
Drug:
tositumomab and iodine I 131 tositumomab
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CCBX001-049
, NCT00078598
2.
Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 80
Sponsor:
NHLBI
Protocol IDs:
384
, BMT CTN 0401, U01 HL069294-05, NCT00329030
3.
Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 80
Sponsor:
NCI, NHLBI
Protocol IDs:
384
, BMT CTN 0401, U01 HL069294-05, NCT00329030
4.
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
J0703
, NA00005743, NCT00484874
5.
Phase II Study of Iodine I 131 Tositumomab, Etoposide, and Cyclophosphamide Followed By Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 59
Sponsor:
NCI
Protocol IDs:
FHCRC-1368.00
, NCT00073918
6.
Phase II Study of Iodine I 131 Tositumomab in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Older Patients With Previously Untreated Bulky Stage II or Stage III or IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SWOG-S0433
, NCT00107380, S0433
7.
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UMCC 2005.035
, NCT00135200
8.
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GSK Protocol #109407
, NCT00475332
9.
Study Looking to See How Effective Fludarabine and Rituximab Followed by Bexxar Are for CLL or SLL
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
PSOC 2301
, IR-6466, NCT00476047
10.
Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
19 and over
Sponsor:
Other
Protocol IDs:
LYMNHL0019
, 95337, LYMNHL0019, NCT00490009, NCT00490009
11.
Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
19 and over
Sponsor:
Other
Protocol IDs:
LYMNHL0046
, 97437, NCT00490490, NCT00490490
12.
Phase I Study of Iodine I 131 Tositumomab and Fludarabine Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation in Older Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
60 and over
Sponsor:
Other
Protocol IDs:
FHCRC-1943.00
, NCT00110071
13.
Phase 1 Study of Radiosensitization Using Bortezomib for Relapsed Mantle Cell or Aggressive Lymphoma Patients in Radioimmunotherapy
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UMCC 2006.045
, NCT00398762
14.
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
UPCC 18406
, UPenn IRB#805353, GSK 106665, NCT00434629
15.
Study of Radioimmunotherapy Comprising Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Non-Hodgkin's Lymphoma
Phase:
No phase specified
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 to 100
Sponsor:
NCI
Protocol IDs:
JHOC-J0636
, NCT00416312
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
